A historical shortage milestone cannot be used as a live permission indicator for a new procurement decision.
Affected arrangements: Semaglutide arrangements relying on shortage-era supply or an asserted patient-specific difference.
Read the date before the claim
FDA's policy page records the semaglutide injection shortage determination of 21 February 2025 and subsequent enforcement updates. These are historical events. The same page contains a later update dated 1 April 2026. A screenshot of an older paragraph can omit the qualification needed for today's decision. Keep the complete source and access date in the review file.
Separate the clinical and supply questions
The existence of a prescription does not settle whether the proposed compounder may make and supply a particular preparation under the asserted pathway. Ask the clinical reviewer to address the patient-related question through appropriate clinical channels. Ask counsel to assess the proposed compounding and dispensing arrangement. The procurement working sheet must contain no patient-identifiable information.
Reassess existing commitments
For an ongoing contract, identify the exact product covered, minimum volumes, cancellation terms, change-in-law language and responsibility for disrupted orders. Document whether the supplier's original rationale has changed. Request a dated written response identifying the current basis asserted, rather than accepting a general assurance that the pharmacy remains licensed.
Use a conditional hand-off
The output should be a list of unresolved questions, named owners and next review dates. Do not describe the arrangement as cleared or automatically prohibited solely because a historical date appears in the file. Do not infer that local stock difficulty recreates a national shortage determination. Obtain qualified review before changing an access arrangement or making a commercial commitment.
Questions to take forward
- Which dated source is the supplier relying on?
- Does the proposed preparation match that source's scope?
- What happens to deposits and open orders if the route changes?
Primary sources & evidence limits
FDA: GLP-1 compounding policies and dated shortage milestones ↗Latest dated update retrieved: 1 April 2026 · Accessed 2026-11-17FDA: Compounding questions and answers ↗Publication date not confirmed · Accessed 2026-11-17Primary-source links were opened or retrieved on 17 November 2026. This date records source access, not legal or clinical review. Procurement checklists and commercial models are editorial methods. No live supplier, licence, coverage or capacity verification has been performed.